It's a pretty common exit strategy to take the company public that allows the original investors or the mezzanine investors to exit but people sometimes forget how much that changes the company just from even... so when you're small or even a medium sized biotech rather than a large business, the pr...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
